Summary & Overview
HCPCS J9024: Injection of Atezolizumab with Hyaluronidase
HCPCS Level II code J9024 denotes an injectable combination of atezolizumab (5 mg) and hyaluronidase-tqjs. As an oncology biologic formulation, this code captures administration of an immunotherapy agent used in cancer care and is relevant for billing in outpatient infusion centers, oncology clinics, and hospital outpatient departments. Nationally, accurate coding for high-cost biologics like atezolizumab affects claims adjudication, patient cost-sharing, and utilization tracking across public and commercial payers.
This analysis covers coverage and benchmark context for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise presentation of what the code represents, typical sites of service, common modifiers in use, and what to expect in payer coverage approaches. The report highlights reimbursement benchmarks, policy updates that affect coding and billing for biologic injectables, and clinical context around administration settings and service lines.
Intended readers include billing professionals, oncology practice managers, revenue-cycle analysts, and policy stakeholders seeking a national perspective on coding, billing implications, and payer handling of injectable immunotherapy agents.
Billing Code Overview
HCPCS Level II code J9024 represents an injection of atezolizumab, 5 mg, combined with hyaluronidase-tqjs. This code describes a pharmacologic oncology therapy formulation intended for administration as an injectable biologic agent.
-
Service type: Injection of a monoclonal antibody immunotherapy (atezolizumab) with facilitating enzyme (hyaluronidase) for subcutaneous or intramuscular administration
-
Typical site of service: Outpatient infusion or oncology clinic; injectable administration in ambulatory care settings or hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A patient with locally advanced or metastatic programmed death-ligand 1 (PD-L1) expressing non-small cell lung cancer (NSCLC) presents to an oncology infusion suite for systemic immunotherapy. The treatment ordered is J9024 (atezolizumab with hyaluronidase) administered via subcutaneous injection as part of scheduled cycle-based therapy. The workflow includes verification of the infusion/therapy order, pre-administration assessment (vitals, weight, review of recent laboratory results such as complete blood count and liver function tests), screening for prior hypersensitivity to monoclonal antibodies or hyaluronidase, and confirmation of concomitant medications. The medication is prepared by pharmacy in accordance with sterile compounding standards and delivered to the clinic. A registered nurse performs site selection and subcutaneous administration, observes the patient for immediate adverse reactions for at least 30–60 minutes as clinically indicated, documents lot numbers and expiration, and records administration details in the medical record and oncology treatment plan. Billing and coding staff append appropriate HCPCS J9024 along with payer-appropriate modifiers and link to the oncologic ICD-10 diagnosis code(s) supporting medical necessity for systemic immunotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/unused |